Company news

Gain Therapeutics, Inc. (NASDAQ:GANX) news

Gain Therapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract…

Gain Therapeutics, Inc. (NASDAQ:GANX) news

Press releases & updates

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Gain Therapeutics to Present at Neuroscience 2025

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

Gain Therapeutics to Participate in Upcoming Investor Conferences

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2